Reversal effect of a novel N-sugar substituted thalidomide analogue on multidrug resistant human nasopharyngeal carcinoma cells

Progress in Biochemistry and Biophysics

Volumn 36, Issue 1, 2009, Pages 58-64

  Yi, Wen Yuan ^a   Xu, Bo ^a   Li, Min ^a   Li, Zhong Jun ^a   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

KB cell; Multidrug resistance; P glycoprotein; TAX; Thalidomide

Indexed keywords

EID: 67650631647     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2008.00307     Document Type: Article

References (20)

1. Rajkumar S V, Hayman S R, Lacy M Q, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed meyloma. Blood, 2005, 106 (13):4050-4053
2. Lokhorst H M, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 2008, 93 (1):124-127
3. Hashimoto Y. Novel biological response modifiers derived from thalidomide. CurrMed Chem, 1998, 5 (3):163-178
4. Inatsuki S, Noguchi T, Miyachi H, et d. Tubulin-polymerization inhibitors derived from thalidomide. Bioorg Med Chem Lett, 2005, 15 (2):321-325
5. Hashimoto Y. Structure development of biological response modifiers based on thalidomide. Bioorg Med Chem, 2002, 10 (3):461-479
6. Lindhorst T K. Essentials of Carbohydrate Chemistry and Biochemistry. Weinheim: Wiley-VCH, 2000. 72
7. Forastiere A A, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer, 1998, 82 (11):2270-2274
8. Chen L, Zhang Q, Zhang H. Modern Oncology, 2005, 13 (5):656-658
9. Xu B, Xing C, Li M, el al. Prog Biochem Biophys, 2007, 34 (5):503-508
10. Atkinson D E, Greenwood S L, Sibley C P, et al. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol, 2003, 285 (3):584-591
11. Pérez-Tomós R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem, 2006, 13 (16):1859-1876
12. Gottesman M M, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett, 2006, 580 (4):998-1009
13. Aragon-Ching J B, Li H, Gardner E R, el al. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discqy, 2007, 2 (2):167-174 ""
14. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111 (8):3968-3977
15. Rajkumar S V, Hayman S, Gertz M A, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 2002, 20 (21):4319-4323
16. Li P K, Pandit B, Sackett D L, et al. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther, 2006, 5 (2) :450-456
17. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96 (9):2943-2950
18. Richardson P G, Schlossman R L, Weller E, et al'., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100 (9):3063-3067
19. Dimopoulous A, Weber D, Chen C, el al. Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica, 2005, 90 (Suppl 2) : 160
20. Fujita T, Washio K, Takabatake D, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoproteinmediated multidrug resistance. Int J Cancer, 2005, 117 (4):670-682